<DOC>
	<DOCNO>NCT00825773</DOCNO>
	<brief_summary>E.V.O.L.U.T.I.O.N . : A Randomized Study Evaluate Safety Efficacy Excel Sirolimus Eluting Stent Biodegradable Polymer Versus Sirolimus Eluting Stent Non-Biodegradable Polymer Treatment Patients de novo Coronary Artery Lesions .</brief_summary>
	<brief_title>A Study Evaluate Safety Efficacy ExcelTM Sirolimus Eluting Stent With Biodegradable Polymer Versus Sirolimus Eluting Stent With Non-Biodegradable Polymer Treatment Patients With de Novo Coronary Artery Lesions</brief_title>
	<detailed_description>E.V.O.L.U.T.I.O.N . : A Randomized Study Evaluate Safety Efficacy Excel Sirolimus Eluting Stent Biodegradable Polymer Versus Sirolimus Eluting Stent Non-Biodegradable Polymer Treatment Patients de novo Coronary Artery Lesions . A prospective , randomize , control , parallel two-arm multi-center study , compare ExcelTM DES CypherTM DES treatment patient de novo coronary artery lesion . To evaluate safety efficacy Excel DES ( biodegradable polymer ) compare Cypher DES ( non-biodegradable polymer ) treatment patient de novo coronary artery lesion . Approximately 1944 patient enrol 25 center China . Primary Endpoint : Ischemia-driven Target Vessel Failure composite cardiac death , myocardial infarction ( Q non-Q wave ) target vessel revascularization ( TVR ) 12 month . Secondary Endpoint : 1 . Ischemia-driven Target Lesion Failure ( TLF ) 12 month define composite cardiac death clearly attribute vessel target vessel , target vessel MI ( Q Non-Q wave ) ischemia-driven TLR . 2 . Rates stent thrombosis , define ( per ARC definition ) definite probable categorize early , late late . 3 . Rates component TLF composite endpoint ( cardiac death , target vessel MI , ischemia- driven TLR ) 12 month post-procedure . 4 . Major Adverse Cardiac Events ( MACE ) define cardiac Death , target vessel MI ( Q Non-Q wave ) , target Lesion revascularization ( TLR ) 30 day , 6 month , 12 month 2 5 year annually . 5 . Device Success define achievement final residual in-stent diameter stenosis &lt; 30 % ( visual estimate ) TIMI flow 3 use Excel/Cypher DES . 6 . Procedure Success define achievement final in- stent diameter stenosis &lt; 30 % ( visual estimate ) TIMI flow 3 use percutaneous method , without occurrence in-hospital MACE . ( ALL TLR IN THIS STUDY WILL BE CLINICALLY INDICATED )</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Death</mesh_term>
	<mesh_term>Chlorhexidine</mesh_term>
	<mesh_term>Chlorhexidine gluconate</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Glucuronyl glucosamine glycan sulfate</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>1 . Patient &gt; 18 year age . 2 . Diagnosis stable angina , unstable angina silent ischemia ( evidence myocardial ischemia ) . 3 . Positive functional study reversible change electrocardiogram ( ECG ) consistent ischemia . 4 . Patient must acceptable candidate coronary artery bypass graft ( CABG ) surgery . 5 . Patient must agree undergo require followup exam inations . Angiographic 1 . Presence one de novo coronary artery stenosis &gt; 50 % native coronary artery correspond evidence ischemia . NOTE : In presence multiple de novo coronary lesion maximum four ( 4 ) plan Excel Cypher stent may use . 2 . The target lesion ( ) must &lt; 24mm length reference diameter &gt; 2.5 mm &lt; 3.75 mm ( visual estimate ) . 1 . Patient pregnant breast feeding . 2 . Patient allergic contraindication aspirin , clopidogrel ticlopidine , heparin bivalirudin , stainless steel , PLA , contrast medium ( adequately pre medicate ) , sirolimus ( analogue ) . 3 . Patient evidence Acute Myocardial Infarction evidence elevation CK/CKMB Troponin per clinical site standard , within 72 hour index procedure . 4 . Patient unable provide inform consent . 5 . Patient participate another device drug study reach primary endpoint study . 6 . Patient consider DES Excel Cypher stent . 7 . Patient comorbid condition ( ) could limit patient 's ability participate study , comply follow requirement impact scientific integrity study . Angiographic 1 . Patient undergone previous stenting anywhere within target vessel ( ) within previous 12 month , require stenting within target vessel ( ) within 12 month study procedure , receive coronary brachytherapy anytime . 2 . Heavily calcify target lesion ( ) successfully predilated . 3 . Target lesion ( ) involve side branch &gt; 2.5 mm diameter , &lt; 2.5 mm diameter require treatment . 4 . Patient unprotected Left Main Coronary Lesion diameter &gt; = 50 % . 5 . Anticipated use rotoblator cut balloon target lesion ( ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>TVF</keyword>
	<keyword>TLF</keyword>
	<keyword>MACE</keyword>
	<keyword>Ischemia-driven Target Vessel Failure ( TVF ) 12 month .</keyword>
	<keyword>Ischemia-driven Target Lesion Failure ( TLF ) 12 month define</keyword>
	<keyword>composite cardiac death clearly attribute vessel</keyword>
	<keyword>target vessel , target vessel MI ( Q Non-Q wave )</keyword>
	<keyword>ischemia-driven TLR .</keyword>
	<keyword>Rates stent thrombosis , define ( per ARC definition ) definite probable</keyword>
	<keyword>categorize early , late late .</keyword>
	<keyword>Major Adverse Cardiac Events ( MACE ) define cardiac death , target</keyword>
	<keyword>vessel MI ( Q Non-Q wave ) , target lesion revascularization ( TLR ) 30</keyword>
	<keyword>day , 6 month , 12 month 2 5 year annually .</keyword>
</DOC>